See the DrugPatentWatch profile for Solifenacin
Solifenacin succinate is a medication used to treat overactive bladder (OAB) with symptoms of urinary urgency, frequency, and urge incontinence. It functions by relaxing the detrusor muscle in the bladder, which helps to increase bladder capacity and reduce involuntary contractions [1].
How does solifenacin succinate work in the body?
Solifenacin succinate is an antimuscarinic agent. It works by blocking the action of acetylcholine, a neurotransmitter that stimulates muscle contractions. In the bladder, acetylcholine causes the detrusor muscle to contract, leading to urination. By blocking acetylcholine receptors, solifenacin succinate inhibits these contractions, thereby alleviating symptoms of OAB [1].
What conditions can solifenacin succinate treat?
This medication is prescribed for adult patients diagnosed with overactive bladder, characterized by symptoms such as sudden urges to urinate, needing to urinate more often than usual, and involuntary leakage of urine [1].
When does patent protection for solifenacin succinate expire?
The patent landscape for solifenacin succinate is complex and can vary by region. However, it is generally understood that the primary patents for the active ingredient and its formulations have expired or are nearing expiry in many major markets, paving the way for generic competition. For detailed patent expiry information, resources like DrugPatentWatch.com can provide specific data [2].
What are the potential side effects of solifenacin succinate?
Common side effects associated with solifenacin succinate include dry mouth, constipation, blurred vision, and indigestion. Less common but more serious side effects can occur, and patients should consult their healthcare provider if they experience any adverse reactions [1].
Are there alternative treatments for overactive bladder?
Yes, alternative treatments for OAB exist, including behavioral therapies (like bladder training and Kegel exercises), other classes of medications such as beta-3 adrenergic agonists, and in some cases, medical devices or surgical options. The choice of treatment depends on individual patient needs and responses [3].
What is the difference between Vesicare and generic solifenacin?
Vesicare is the brand-name medication containing solifenacin succinate. Generic versions of solifenacin succinate are bioequivalent to Vesicare, meaning they contain the same active ingredient and are expected to have the same safety and efficacy profile. Generic options typically become available after the expiration of the brand-name drug's patents and can offer a more affordable alternative [2].
What is the cost of solifenacin succinate tablets?
The cost of solifenacin succinate tablets can vary significantly depending on whether one is purchasing the brand-name Vesicare or a generic version, as well as the dosage, quantity, and insurance coverage. Generic versions are generally less expensive than the brand-name drug [2].
Who manufactures solifenacin succinate?
The original manufacturer of Vesicare is Astellas Pharma. However, with patent expiries, numerous pharmaceutical companies now produce and market generic versions of solifenacin succinate tablets [2].
---
Sources:
[1] https://www.drugpatentwatch.com/solifenacin-succinate
[2] https://www.drugpatentwatch.com/
[3] https://www.nhs.uk/conditions/overactive-bladder/